ESTRO25: What’s Happening on Day 3
As Day 3 of the ESTRO25 Congress unfolded in Vienna, the Austria Center buzzed with relentless momentum and fresh insights. With two high-impact days already behind them, attendees returned with renewed energy—ready to challenge paradigms, share progress, and reimagine the future of radiation oncology.
The agenda was once again packed with game-changing research, clinical breakthroughs, and bold conversations that bridged disciplines and borders. Whether it was a session on emerging technologies or a deep dive into survivorship strategies, Day 3 reaffirmed ESTRO’s mission: to lead with science, collaborate across specialties, and ultimately improve the lives of patients worldwide.
In this post, we bring you the standout moments from Day 3—where curiosity met compassion, and where the global oncology community came together not just to inform, but to inspire.
“Not my usual area of interest but supporting team Glasgow.
Great to see a packed plenary hall for Campbell Roxburgh presenting results of PRIME RT in rectal cancer.”
Personalized treatment decisions should be made for BRCA carriers. RT is safe and more studies are needed to evaluate the safety of concurrent Olaparib and RT.
“SYMPOSIUM at ESTRO25
Breast cancer in young patients.
Breast cancer in younger patients: The patient voice. Excellent talk by Tanja Spanic.”
Remember to care for a person, not just a patient.”
“PLATO ACT 4: Ph II RCT of 50.4 vs. 41.4 Gy for T1-2 (<4 cm) N0 anal SCC.
No difference in 3-year local recurrence (primary endpoint) or OS, & better toxicity/QOL with dose-reduction.
Should 41.4 Gy be a SOC option (ahead of Ph III DECREASE trial reporting)?”
“Second breast-conserving surgery: What should I do? Vademecum for a perfect multidisciplinary meeting”
It was such a great pleasure to be involved in the “Multidisciplinary Tumour Board” at ESTRO25 alongside Hannoun Jean, Kaidar Orit.”
“Amazing Reirradiation Meet&Greet session at ESTRO25 today!
Fantastic turnout, and great opportunity to present how much we’ve already done on reirradiation in ESTRO Now really looking forward to working with all the new members of the Reirradiation Focus group.”
“Breast Cancer Focus Group at ESTRO25 chaired by Sofia Rivera.
A great meeting today to develop future projects with an amazing team, thanks a lot!”
“Proud of our Medical Physics team and Livia Marrazzo presenting ESTRO25 automated treatment planning implantation and performance in clinical practice in breast cancer.”
“Nina Niu Sanford with a fantastic talk on radiation omission trials!
Proposing suggestions for optimizing the design and implementation of RT omission trials going forward, emphasizing the importance of fostering collaboration between oncologic specialties.”
“SBRT + in oligomets:
2294 pts | Lung, breast, prostate, colorectal
Grade 3+ AEs: 1.5%
SBRT Safe with systemic tx!”
“Powerful reminder at ESTRO25 today:
Patient Advocacy is not optional — it’s essential Superb talk by Tanja Spanic in the Breast Cancer in Young Patients session ESTRO25 Young women deserve a voice in decisions, research, and survivorship care.”
“Bounce (defined as an increase > 0.2 ng/mL) following ultra hypofrac radiotherapy, is frequent (36%) & associated with improved prognosis. Data from HYPO RT PC at ESTRO25 Possible bias (bounces by definition have a decrease in PSA after the rise) role of 3y landmark analysis.”
“Honored to co-chair the Genitourinary session at ESTRO25 — a first for someone from Serbia . The room was packed, the trials impressive, and the speakers outstanding. Proud to represent my Clinical Center, my country, and our region. We need more visibility for our doctors — this is a step forward.
Grateful to the organizers.”
“Great talk by super @itrisabel at ESTRO25 on how to counsel young BRCA carriers with BreastCancer…stay tuned for an important paper coming out this week to help in this counseling.”
“Italians at ESTRO25.”
“Adjuvant breast RT trials ESTRO25
Fast forward 10-yr update : 26Gy/5 (but not 27Gy/5?! ) non-inf to 40Gy/15 for IBR, similar RFI and OS
Skagen-1: 50Gy/25# > 40Gy/15# for breast ca mortality Time to look beyond EQD2?”
“I’m proud to be one of the 19 mentees selected for the ESTRO Mentoring Programme and to represent my country on the ESTRO mentee map.
Thank you ESTRO for this opportunity. It’s only just begun, and I’m already feeling inspired and full of motivation!”
ESTRO25 is officially underway — and we’re bringing you daily highlights, hot takes, and stories straight from the heart of the meeting. Stay tuned!
Don’t miss out on –
Kicking Off ESTRO25: What’s Happening on Day 1
ESTRO25: What’s Happening on Day 2
Written by Md Foorquan Hashmi, MD, Sr. Editor, OncoDaily: India Bureau
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023